Nick Pirooz

Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, an...

Belantamab mafodotin plus bortezomib and dexamethasone in patiënten met relapsed or refractory multiple myeloma (DREA...

Belantamab mafodotin plus bortezomib-dexamethason bij myeloom: DREAMM-7 fase III